APIM Therapeutics

APIM THERAPEUTICS IS A BIOTECHNOLOGY COMPANY DEDICATED TO THE DEVELOPMENT OF NOVEL ANTI-CANCER AGENTS TARGETING THE DNA DAMAGE RESPONSE. At APIM THERAPEUTICS AS we focus on the development and commercialization of novel combinatorial therapies in cancer cells. Our approach is based on targeting PCNA, a master "hub" protein regulating cell responses to stress e.g. upon DNA Damage Response triggered by several anti-cancer agents (chemotherapy & targeted agents). Through development of first-in-class peptide drugs which contain a novel PCNA-interacting Peptide Motif termed APIM, the company offers a novel intervention point allowing cancer-specific tumor cell elimination. The company's lead drug, ATX-101, is set to enter the clinic in 2016.